



Updated Monthly
September 6, 2023

THE ESSENTIAL GUIDE TO
**Non-Dilutive
Government Funding**

Published by:



Questions?

Liz Powell, Esq., MPH
lpowell@G2Gconsulting.com
www.G2Gconsulting.com

  @G2Gconsulting





TABLE OF CONTENTS

New Opportunities

Aging.....	2
Biotechnology and Biomanufacturing.....	3
Cancer	3
Cardiovascular and Pulmonary Health.....	4
Chronic Pain & Pain Management	5
Cognitive and Brain Health.....	6
Dental and Craniofacial Research	8
Diagnostics	9
Endocrine and Metabolic Diseases	9
Health IT & Data	9
HIV/AIDS	9
Immunology & Infectious Disease	10
Mental Health.....	10
Military Prototype Advancement Initiative.....	11
Patient-Centered Research	11
Reproductive Health.....	12
Sleep Health	12

GBG Report

Updated Monthly

September 6, 2023

<https://www.g2gconsulting.com/gbg-reporting-service/>

Small Business Development	13
Substance Use Disorder	13

Recurring Opportunities

Advanced Research Projects Agency for Health	15
Air Force	15
Army.....	16
BARDA	18
DARPA	18
Defense Threat Reduction Agency	18
Department of Energy	19
National Science Foundation	19
Navy	20

GBG Acronyms	21
--------------------	----



September 15, 2023 – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 10-10:30am EST (FREE and open to all) then from 10:30-11am EST (premium service and private consultation for G2G and GBG customers).

Did you miss the Military Health System Research Symposium? G2G posted [daily updates on our blog](#).

Just announced: [BARDA Industry Day](#), November 13-14, 2023, at the Grand Hyatt Washington and Virtual. G2G will be there!

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AGING (4)		
1.	NIA REDI: Entrepreneurial Small Business Transition Award (R43/R44/R41/R42 CT Optional) (NIH/NIA) RFA-AG-24-042 (R43/R44) RFA-AG-24-043 (R41/R42)	These NOFOs invite Research and Entrepreneurial Development Immersion (REDI) SBIR and STTR applications. The goal is to foster the career development of early-career scientists with an interest in entrepreneurship by simultaneously supporting their entrepreneurial development and facilitating their transition to industry. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-042.html (R43/R44) https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-043.html (R41/R42)	Up to \$295,924, for up to 2 years (Phase I) Up to \$1,972,828, for up to 3 years (Phase II)	Letter of intent: 9/26/23 Proposal: 10/26/23
2.	Elucidating Variability of Physiologic and Functional Responses to Exercise Training in Older Adults (R01 CT Required) (NIH/NIA) RFA-AG-24-045	This NOFO encourages studies that identify systemic modulators, biomarkers, and other potential mechanisms underlying exercise variation in outcomes that are clinically relevant for older adults. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-045.html	Up to \$1 million, for up to 5 years	Letter of intent: 10/3/23 Proposal: 11/3/23
3.	Healthy Aging: Optimizing Physical and Mental Functioning Across the Aging Continuum -- Cycle 3 2023 (PCORI)	The Healthy Aging Targeted PCORI Funding Announcement will solicit applications for CER studies that focus on different phases of the aging continuum and aim to achieve one or more of the following four goals: maintaining function and independence; facilitating chronic disease management; supporting individuals with significant functional impairment; reducing caregiving burden and improving quality of life. https://www.pcori.org/funding-opportunities/announcement/healthy-aging-optimizing-physical-and-mental-functioning-across-aging-continuum-cycle-3-2023	Up to \$10 million, for up to 5 years	Letter of intent: 10/3/23 Proposal: 1/9/24

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOTECHNOLOGY AND BIOMANUFACTURING (1)		
4.	23-01: Manufacturing Optimization (MCDC) RPP-23-01	Under this prototype project, the Government is seeking optimized manufacturing platforms/techniques that can be seamlessly incorporated into an integrated emergency response system that covers the entire drug development lifecycle. Innovative manufacturing solutions will support a 100-day target timeline for advancing drug development from pathogen identification through fielding of doses. Manufacturing is a critical component within that timeline. Reduction of manufacturing schedules, while maintaining quality and productivity, will require highly innovative approaches, technologies, and regulatory strategies. https://www.medcbrn.org/solicitations/	TBD	Proposal: 9/25/23 Applicants must be MCDC members
		CANCER (15)		
5.	Precision Surgical Interventions (PSI) Broad Agency Announcement (BAA) (ARPA-H) 75N99223R0004	The PSI program aims to develop technologies to aid surgeons to complete procedures with high accuracy, dramatically reducing inadvertent errors and reoperation rates. More specifically, PSI seeks to develop intraoperative end-to-end solutions for enhanced visualization of cancerous tissues. These solutions, available at the bedside or in vivo will allow physicians to visualize with microscopic precision where cancer ends, enabling them to accurately complete all oncological surgeries and reduce reoperations. https://sam.gov/opp/c17fabdf578b481096aaacodebcbf27b/view	Dependent upon proposal and available funding	Abstract: 9/21/23 Invited proposal: 11/16/23
6.	Pre-Announcement: Pre-Cancer Atlas (PCA) and Human Tumor Atlas (HTA) Research Centers (U01 Clinical Trial Not Allowed) (NIH/NCI) NOT-CA-23-085 NOT-CA-23-086	HTAN is a collaborative research initiative and a community resource generating program that is tasked with generating spatial atlases of cancer transitions for a diverse set of precancers and advanced cancers that build upon the current set of public HTAN atlases. The objective of each PCA Research Center is to construct one multimodal, dynamic, and spatial atlas of a precancerous lesion by conducting comprehensive molecular, cellular, and tissue characterization of a human precancerous lesion and its microenvironment with spatial resolution. The objective of each HTA Research Center will be to construct no more than one tumor atlas that describes the molecular, cellular, and tissue-level spatial, functional, and/or temporal relationships of cellular and non-cellular components of the tumor ecosystem. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-23-085.html https://grants.nih.gov/grants/guide/notice-files/NOT-CA-23-086.html	Up to \$800,000 per year, for up to 5 years	Estimated post date: 9/29/23 Estimated proposal date: 12/5/23
7.	NOSI: Mechanisms Driving Obesity and Prostate Cancer Risk (NIH/NCI) NOT-CA-23-089	The purpose of this NOSI is to promote studies examining the mechanisms by which obesity drives aggressive prostate cancer (PCa) risk. The identification of differences in the mechanisms driving aggressive vs. overall disease are critical to optimizing clinical care among men who develop the disease. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-23-089.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/8/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
8.	Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) (NIH/NCI) PAR-23-264	The NCI intends to stimulate research in discovery and development of novel, small molecules for cancer. Molecules discovered through this NOFO may be used to probe cancer biology, to validate cancer targets, or as the basis for optimized drugs. https://grants.nih.gov/grants/guide/pa-files/PAR-23-264.html	Dependent upon proposal, for up to 3 years	Letter of intent: 1/5/24 Proposal: 2/5/24
9.	Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required) (NIH/NCI) PAR-23-273	This NOFO solicits mechanistic research that aims to understand how and why expectancy effects occur in a cancer context, elucidate their role in cancer symptom management, and identify patients, symptoms, cancer sites, and contexts in which expectancy effects can be leveraged to improve cancer outcomes. https://grants.nih.gov/grants/guide/pa-files/PAR-23-273.html	Dependent upon proposal, for up to 5 years	Proposal: 10/5/23
10.	Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 CT Optional/R21 CT Not Allowed) (NIH/NCI) PAR-23-279 (R01) PAR-23-280 (R21)	These NOFOs invite applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/ glucose dependent insulinotropic polypeptide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. https://grants.nih.gov/grants/guide/pa-files/PAR-23-279.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-23-280.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000 per year, for up to 2 years (R21)	Letter of intent: 1/5/24 Proposal: 2/5/24 (R01) Letter of intent: 1/16/23 Proposal: 2/16/24 (R21)
11.	Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 CT Not Allowed) (NIH/NCI) PAR-23-281	The NCI, through this NOFO encourages submission of projects devoted to demonstrating that mammalian models, including organoids, tumoroids and cell models, used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patient benefit. https://grants.nih.gov/grants/guide/pa-files/PAR-23-281.html	Up to \$499,000 per year, for up to 5 years	Proposal: 10/5/23
		CARDIOVASCULAR AND PULMONARY HEALTH (3)		
12.	Pre-Announcement: NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional) (NIH/NHLBI) NOT-HL-23-109	This NOFO intends to support studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. https://grants.nih.gov/grants/guide/notice-files/NOT-HL-23-109.html	Up to \$450,000, for up to 3 years	Estimated post date: 1/1/24 Estimated proposal date: 2/16/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CARDIOVASCULAR AND PULMONARY HEALTH		
13.	Pre-Announcement: NHLBI Program Project Applications (Po1 Clinical Trials Optional) (NIH/NHLBI) NOT-HL-23-114	The NHLBI Program Project Grant supports research related to fundamental processes and diseases of the heart, blood and lymphatic vessels, lungs, and blood, including transfusion medicine, blood resources, and sleep disorders other programs including implementation science, health disparities, and translation research that address the mission of the Institute. This NOFO requires a minimum of three interrelated research projects that investigate a complex biomedical theme or research question. https://grants.nih.gov/grants/guide/notice-files/NOT-HL-23-114.html	TBD	Estimated post date: 11/1/23 Estimated proposal date: 1/25/24
14.	Cardiovascular Health Topical PCORI Funding Announcement -- Cycle 3 2023 (PCORI)	This PFA will fund comparative clinical effectiveness research (CER) on key decisional dilemmas in the fields of cardiovascular disease (CVD) prevention, screening, diagnosis, treatment, and posttreatment recovery and studies that focus on interventions and care delivery strategies that improve cardiovascular health outcomes in populations experiencing disparities. https://www.pcori.org/funding-opportunities/announcement/cardiovascular-health-topical-pcori-funding-announcement-cycle-3-2023	Up to \$12 million, for up to 5 years	Letter of intent: 10/3/23 Proposal: 1/9/24
		CHRONIC PAIN & PAIN MANAGEMENT (5)		
15.	HEAL Initiative: HEAL KIDS (Knowledge, Innovation and Discovery Studies) Pain: Acute Pain Clinical Trials Program (U01 CT Required) and Pain Program Resource and Data Center (U24 CT Not Allowed) (NIH) RFA-HD-24-011 (U01) RFA-HD-24-012 (U24)	These NOFOs support innovative, multi-site, large-scale investigator-initiated clinical trials to advance the understanding, assessment, measurement, treatment, and prevention of acute pain in infants, children, and adolescents; and a single HEAL KIDS Pain Resource and Data Center. https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-24-011.html (U01) https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-24-012.html (U24)	Up to \$2.1 million per year, for up to 5 years (U01) Up to \$600,000, for 6 years (U24)	Letter of intent: 10/20/23 Proposal: 11/20/23
16.	HEAL Initiative: Understanding Individual Differences in Human Pain Conditions (R01 - Clinical Trial Optional) (NIH) RFA-NS-24-021	This NOFO seeks to support research aimed at holistic understanding of inter-individual or between-person differences in human pain conditions, focusing on 'Whole Person Health' and enhancing pain treatment and management strategies towards personalized pain medicine. Applicants are encouraged to develop and implement novel, multidisciplinary research approaches, and include investigators with complementary expertise to fulfill the project and program goals. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-021.html	Up to \$650,000 per year, for up to 5 years	Proposal: 11/7/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CHRONIC PAIN & PAIN MANAGEMENT		
17.	HEAL INITIATIVE: Development and validation of remote or patient wearable device derived objective biosignatures or functional assessments to monitor pain for use as endpoints in clinical trials (UG3/UH3 -CT Optional) (NIH) RFA-NS-24-023	This NOFO aims to promote the discovery, development, and validation of real-world digital endpoints derived from data generated by existing remote or wearable devices. These endpoints will be used for monitoring the experience of pain, its progression, response to interventions, and impact on quality of life. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-023.html	Up to \$500,000 per year, for up to 2 years (UG3) Up to \$1.5 million per year, for up to 3 years (UH3)	Letter of intent: 12/30/23 Proposal: 1/30/24
18.	Telehealth to Optimize Management of Multiple Chronic Conditions among Vulnerable Populations in Primary Care -- Cycle 3 2023 (PCORI)	This FOA is soliciting applications that respond to the following question: What is the comparative clinical effectiveness of different approaches to incorporating access to and use of telehealth to optimize management of multiple chronic conditions in primary care, particularly among vulnerable populations? Applications should focus on community-dwelling individuals with multiple chronic conditions and should be powered to allow for conclusions regarding one or more vulnerable populations of interest. https://www.pcori.org/funding-opportunities/announcement/telehealth-optimize-management-multiple-chronic-conditions-among-vulnerable-populations-primary-care-cycle-3-2023	Up to \$10 million, for up to 5 years	Letter of intent: 10/3/23 Proposal: 1/9/24
		COGNITIVE AND BRAIN HEALTH (11)		
19.	NOSI: Investigation of Biomolecular Condensates in Aging and Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (NIH/NIA) NOT-AG-23-037	This NOSI invites research that investigates cell-specific mechanisms of BMC formation and function, investigate the role the NPC plays in regulating BMC formation and cell specific impact, and exploit existing tools or develop new tools to study the neurobiology of BMCs in aging and AD/ADRD. https://grants.nih.gov/grants/guide/notice-files/NOT-AG-23-037.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 11/13/24
20.	Pre-Announcement: BRAIN Initiative Connectivity across Scales Data Coordinating Center (BRAIN CONNECTS DCC) (U24 Clinical Trial Not Allowed) (NIH) NOT-NS-24-009	Through the intended NOFO, NIH expects to fund one or more BRAIN CONNECTS DCCs, which will collaborate with the data generating projects to (1) coordinate activities of the BRAIN CONNECTS Network, (2) develop and harmonize common data processing pipelines, (3) integrate and disseminate data analytic tools and capabilities, (4) establish a unified knowledge base for connectivity data of diverse modalities, and (5) organize and implement outreach and engagement to the wider research community and the general public. https://grants.nih.gov/grants/guide/notice-files/NOT-NS-24-009.html	Dependent upon proposal, for up to 5 years	Estimated post date: 10/16/23 Estimated proposal date: 12/15/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH		
21.	Analytical and Clinical Validation of Biomarkers for Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Optional) (NIH/NIA) PAR-23-258	This NOFO invites applications to accelerate the establishment of effective and reliable biomarkers of AD/ADRD for use in therapy/medical product discovery and development, clinical trials, and/or clinical practice. Specifically, this NOFO will support analytical and/or clinical validation of a biomarker, composite biomarker, or biomarker signature. https://grants.nih.gov/grants/guide/pa-files/PA-23-258.html	Dependent upon proposal, for up to 5 years	Letter of intent: 10/3/23 Proposal: 11/3/23
22.	Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required) (NIH/NIA) PAR-23-274	This NOFO invites applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for AD/ADRD. Candidate interventions evaluated through this program must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum. https://grants.nih.gov/grants/guide/pa-files/PA-23-274.html	Dependent upon proposal, for up to 5 years	Letter of intent: 1/19/24 Proposal: 2/21/24
23.	Building Neuroscience Research Infrastructure for Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) in Africa (UG3/UH3 Clinical Trial Not Allowed) (NIH/NIA) RFA-AG-24-027	This NOFO promotes collaborative research programs to support the development/enhancement of infrastructure for AD/ADRD neuroscience research in LMICs in Africa, as defined by the World Bank. The research infrastructure programs are expected to contribute to the long-term goals of building sustainable AD/ADRD neuroscience research capacity and research, with the aim of ultimately leading to prevention and mitigation strategies for AD/ADRD in Africa. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-027.html	Up to \$400,000 per year, for up to 3 years (UG3) Up to \$800,000 per year (UH3) Project must not exceed 6 years	Letter of intent: 1/12/24 Proposal: 2/14/24
24.	Neural and Non-Neural Mechanisms Underlying Gait as a Preclinical Marker for Alzheimer's Disease and Alzheimer's Disease-Related Dementias (R01 CT Optional) (NIH/NIA) RFA-AG-24-041	This NOFO invites applications that investigate the neural and/or non-neural mechanisms that underlie the association between gait and cognition in aging and AD/ADRD. Elucidating these mechanisms would help inform the potential use of changes in gait as an early biomarker of AD/ADRD or inform the design of early interventions for AD/ADRD. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-041.html	Up to \$700,000 per year, for up to 5 years	Letter of intent: 10/3/23 Proposal: 11/3/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH		
25.	Chimeric Antigen Receptor (CAR) Approaches to AD/ADRD (R61/R33 Clinical Trial Not Allowed) (NIH/NIA) RFA-AG-24-046	This NOFO aims to provide a proof-of-principle for a novel strategy for AD/ADRD immunotherapies. Specifically, the goal is to examine whether a novel immunotherapeutic approach in cancer immunotherapy with chimeric antigen receptor (CAR) immune cells can be customized as treatments for AD/ADRD. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-046.html	Dependent upon proposal, for up to 5 years	Letter of intent: 1/7/24 Proposal: 2/7/24
26.	VCID Center Without Walls for Understanding and Leveraging Small Vessel Cerebrovascular Disease Mechanisms in ADRD (R01 - Clinical Trial Not Allowed) (NIH/NIA/NINDS) RFA-NS-24-027	This NOFO supports research designed to, in parallel in human-based and model-based studies, advance fundamental understanding of basic disease-related molecular mechanisms of VCID. Specifically, this NOFO solicits applications focused on molecular mechanisms of small cerebral vessel diseases that contribute to dementia diagnoses. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-027.html	Up to \$1 million per year, for up to 5 years	Letter of intent: 12/15/23 Proposal: 2/1/24
		DENTAL AND CRANIOFACIAL RESEARCH (3)		
27.	Collaborative Science to Achieve Disruptive Innovations in Dental, Oral and Craniofacial (DOC) Research (RM1 Clinical Trial Not Allowed) (NIH/NIDCR) RFA-DE-24-003	This NOFO is designed to support highly integrated research teams to address challenging questions with the potential to significantly advance dental, oral and craniofacial (DOC) fields of research. Teams are encouraged to consider transformative, and disruptive innovative objectives with defined 5-year outcomes. https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-24-003.html	Up to \$750,000 per year, for up to 5 years	Letter of intent: 10/23/23 Proposal: 11/22/23
28.	Developing Salivary Components as Therapeutics for Oral Health (R01/R21 Clinical Trial Not Allowed) (NIH/NIDCR) RFA-DE-24-004 (R01) RFA-DE-24-005 (R21)	These NOFOs encourage interdisciplinary research that harnesses the functional components of saliva towards therapeutics. Applications in response to this funding opportunity will aim to develop salivary components to restore health and resilience of the oral cavity. It is expected that outcomes from this research will facilitate development of highly effective surrogate saliva for clinical applications. https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-24-004.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-24-005.html (R21)	Up to \$500,000 per year, for up to 5 years (R01) Up to \$275,000 per year, for up to 2 years (R21)	Letter of intent: 10/1/23 Proposal: 11/1/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DIAGNOSTICS (1)		
29.	Diagnostic Centers of Excellence for the Undiagnosed Diseases Network (U01 – CT Not Allowed) (NIH) PAR-23-289	This NOFO aims to solicit applications for clinical sites that will provide expert diagnostic services for undiagnosed diseases across the nation. The DCoEs will establish collaborations and efficient processes with the Data Management and Coordinating Center; enroll and evaluate new participants; and foster scientific discovery. https://grants.nih.gov/grants/guide/pa-files/PAR-23-289.html	Up to \$500,000 per year, for up to 4 years	Letter of intent: 10/3/23 Proposal: 11/3/23
		ENDOCRINE AND METABOLIC DISEASES (2)		
30.	NOSI: Next-Generation Approaches to Renal Replacement Therapy Including Vascular Access (NIH) NOT-DK-23-015	This NOSI aims to support the development of innovative approaches to renal replacement therapy and address critical accompanying challenges such as vascular access and fluid management during dialysis. https://grants.nih.gov/grants/guide/notice-files/NOT-DK-23-015.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 4/7/25
		HEALTH IT & DATA (3)		
31.	Early-stage, and Enhancement and Management of Established Biomedical Data Repositories and Knowledgebases (R24/U24 Clinical Trial Not Allowed) (NIH) PAR-23-236 (R24) PAR-23-237 (U24)	These NOFOs support the development of early-stage or new data repositories and knowledgebases that could be valuable for the biomedical research community; and established biomedical data repositories and knowledgebases as distinct and separate resources that have demonstrated impact and have potential for continued benefit to the community served. https://grants.nih.gov/grants/guide/pa-files/PAR-23-236.html (R24) https://grants.nih.gov/grants/guide/pa-files/PAR-23-237.html (U24)	Dependent upon proposal, for up to 5 years (R24) Up to \$350,000 per year, for up to 4 years (U24)	Letter of intent: 11/26/23 Proposal: 1/25/24
32.	Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 CT Optional) (NIH/NLM) PAR-23-245	This NOFO seeks applications to advance the development of novel informatics and data science approaches that can help individuals understand and improve their health through actionable insights. https://grants.nih.gov/grants/guide/pa-files/PAR-23-245.html	Up to \$250,000 per year, for up to 4 years	Proposal: 10/5/23
		HIV/AIDS (5)		
33.	Planning for Product Development Strategy (R34 Clinical Trial Not Allowed) (NIH/NIAID) PAR-24-029	This NOFO will support the development of a comprehensive and well-defined product development strategy for next-generation treatments for HIV and HIV-associated comorbidities, coinfections and complications and preventive strategies for HIV, as well as facilitating the translation of research findings into drug products that enables submission of an Investigational New Drug (IND) application to the FDA. https://grants.nih.gov/grants/guide/pa-files/PAR-24-029.html	Up to \$225,000, for up to 1 year	Letter of intent: 2/13/24 Proposal: 3/13/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HIV/AIDS		
34.	Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R01/R21/R34 Clinical Trial Optional) (NIH) RFA-MH-24-160 (R01) RFA-MH-24-161 (R21) RFA-MH-24-162 (R34)	These NOFOs invite applications to understand factors that impact uptake and adherent and persistent use of biomedical HIV prevention options, to inform and advance approaches to support choice and use among these options, and to understand and advance equitable delivery of biomedical HIV prevention options for cisgender and transgender women in settings where multiple prevention options are available. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-24-160.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-24-161.html (R21) https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-24-162.html (R34)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21) Up to \$450,000, for up to 3 years (R34)	Letter of intent: 10/22/23 Proposal: 11/22/23
35.	Biotypes of CNS Complications in People Living with HIV (P01 Clinical Trial Not Allowed) (NIH) RFA-MH-24-235	The goal of this NOFO is to understand the heterogeneity of CNS outcomes in people with HIV on ART, employing quantitative assessments that are linked to psychopathology to identify distinct disease phenotypes, known as biotypes. This NOFO encourages research studies to aid in the identification/ validation of biologically quantifiable readouts in domestic and international settings. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-24-235.html	Dependent upon proposal, for up to 5 years	Letter of intent: 11/11/23 Proposal: 12/11/23
		IMMUNOLOGY & INFECTIOUS DISEASE (1)		
36.	Research Tools for Difficult to Culture Eukaryotic Pathogens (R61/R33 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-23-055	This NOFO supports high risk, milestone-driven approaches for the development of robust culture techniques, and/or genetic and molecular tools to better understand the biology of select human eukaryotic pathogens including the microsporidian <i>Enterocytozoon bieneusi</i> ; <i>Pneumocystis jirovecii</i> ; <i>Plasmodium vivax</i> ; and <i>Babesia microti</i> . https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-055.html	Up to \$250,000 per year, for up to 3 years (R61) Up to \$350,000 per year, for up to 2 years (R33)	Letter of intent: 1/2/24 Proposal: 2/4/24
		MENTAL HEALTH (1)		
37.	Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes: Assay and Data Generation Centers (RM1 Clinical Trial Not Allowed) (NIH/NIMH) RFA-MH-25-145	The long-term goal of SSPsyGene is to systematically characterize the function of neurodevelopmental and psychiatric disorder (NPD) risk genes, across biological scales of organization. This specific NOFO seeks applications for ADGCs, which will be responsible for developing and carrying out high and moderate-throughput assays to characterize the CNS function of a set of NPD risk genes using relevant experimental systems. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-145.html	Dependent upon proposal, for up to 5 years	Letter of intent: 12/31/23 Proposal: 1/31/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MILITARY PROTOTYPE ADVANCEMENT INITIATIVE (1)		
38.	Pre-Announcement: Military Prototype Advancement Initiative (MPAI) (MTEC)	This RPP solicits a broad range of medical prototype technological and knowledge solutions related to the Focus Areas. Proposed solutions may include medical techniques, knowledge products, and materiel. The focus areas are: Combat Casualty Care, Military Infectious Diseases, Military Operational Medicine, and USAF School of Aerospace Medicine. Topics include Precision Medicine, Carcinogens, Wound Management/Burn Healing, and Infection Prevention. https://mtec-sc.org/wp-content/uploads/2023/08/MTEC-FY2023-MPAI-Pre-Announcement.pdf	Dependent upon proposal	TBD
		PATIENT-CENTERED RESEARCH (6)		
39.	Phased Large Awards for Comparative Effectiveness Research -- Cycle 3 2023 (PCORI)	This PFA invites applications for high-quality comparative clinical effectiveness research (CER) projects that will address critical decisions faced by patients, caregivers, clinicians, and stakeholders across the health and healthcare community and for which there is insufficient evidence. Applications must address at least one of the following National Priorities for Health. https://www.pcori.org/funding-opportunities/announcement/phased-large-awards-comparative-effectiveness-research-placer-cycle-3-2023	Up to \$22 million, for up to 6.5 years	Letter of intent: 10/3/23 Proposal: 1/9/24
40.	Advancing the Science of Engagement PCORI Funding Announcement -- Cycle 3 2023 (PCORI)	This PFA will fund studies that build an evidence base on engagement in research, including: Measures to capture structure/context, process, and outcomes; Techniques that lead to effective engagement; How these techniques should be modified and resourced for different contexts, settings, and communities to ensure equity; How engagement supports successful research. https://www.pcori.org/funding-opportunities/announcement/advancing-science-engagement-pcori-funding-announcement-cycle-3-2023	Up to \$1.5 million, for up to 3 years	Letter of intent: 10/3/23 Proposal: 1/9/24
41.	Broad Pragmatic Studies Funding Announcement -- 2023 Standing PFA (PCORI)	This PFA invites applications for high-quality comparative clinical effectiveness research projects. All applications must align the proposed research with at least one of the National Priorities for Health. Applicants have the option to choose up to three of twelve topic themes , based on how their proposed research aligns. https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-funding-announcement-2023-standing-pfa-cycle-3	Up to \$10 million, for up to 5 years Dependent upon award mechanism	Letter of intent: 10/3/23 Proposal: 1/9/24
42.	Improving Methods for Conducting Patient-Centered Outcomes Research -- 2023 Standing PFA (PCORI)	For this PFA, PCORI has identified the following areas as programmatic priorities: Methods to Improve the Use of AI and ML in Clinical Research; Methods to Improve Study Design; Methods to Support Data Research Networks; Methods Related to Ethical and Human Subjects Protections Issues in PCOR/CER. https://www.pcori.org/funding-opportunities/announcement/improving-methods-conducting-patient-centered-outcomes-research-2023-standing-pfa-cycle-3	Up to \$750,000, for up to 3 years	Letter of intent: 10/3/23 Proposal: 1/9/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED RESEARCH		
43.	Implementation of Effective Shared Decision Making Approaches in Practice Settings -- Cycle 3 2023 (PCORI)	This initiative will support projects that propose active, multi-component approaches to implementing effective shared decision making strategies that address existing barriers and obstacles to uptake and maintenance, so that these interventions are effectively and sustainably integrated into practice. The SDM strategy must have demonstrated effectiveness on patient, caregiver, or healthcare provider decision making using widely accepted metrics; the corresponding implementation approach must have potential for use and scalability beyond the targeted implementation setting. https://www.pcori.org/funding-opportunities/announcement/implementation-effective-shared-decision-making-approaches-practice-settings-cycle-3-2023	Up to \$2.5 million, for up to 3 years	Letter of intent: 10/3/23 Proposal: 1/9/24
44.	Open Competition PFA: Implementation of Findings from PCORI's Major Research Investments -- Cycle 3 2023 (PCORI)	For this PFA, PCORI has identified the following four areas of eligible evidence: Obesity Treatment in Primary Care Settings; Nonsurgical treatment options can improve or eliminate symptoms for women with urinary incontinence (UI); Several kinds of therapy and medicines can reduce or stop symptoms for people with PTSD; The use of narrow-spectrum versus broad-spectrum antibiotics to treat children's acute respiratory tract infections (ARTIs). https://www.pcori.org/funding-opportunities/announcement/open-competition-pcori-funding-announcement-implementation-findings-pcoris-research-investments-cycle-3-2023	Up to \$2.5 million, for up to 3 years	Letter of intent: 10/3/23 Proposal: 1/9/24
		REPRODUCTIVE HEALTH (1)		
45.	National Centers for Translational Research in Reproduction and Infertility (NCTRI) (P50 Clinical Trial Optional) (NIH/NICHD) RFA-HD-24-010	This NOFO provides funding for a limited number of research centers in the reproductive sciences. These centers provide an arena for multidisciplinary interactions among basic and clinical scientists interested in establishing high quality translational research programs in these scientific areas. These centers will form a national network that facilitates and accelerates bidirectional knowledge transfer between the laboratory and clinic with the ultimate goal of improving human reproductive health through research excellence and innovation. https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-24-010.html	Up to \$1.1 million per year, for up to 4 years	Letter of intent: 10/29/23 Proposal: 11/29/23
		SLEEP HEALTH (1)		
46.	Sleep Health Topical PCORI Funding Announcement -- Cycle 3 2023 (PCORI)	This PFA will fund high-quality, comparative clinical effectiveness research (CER) projects that focus on sleep health. delivery strategies that improve cardiovascular health outcomes in populations experiencing disparities. https://www.pcori.org/funding-opportunities/announcement/sleep-health-topical-pcori-funding-announcement-cycle-3-2023	Up to \$12 million, for up to 5 years	Letter of intent: 10/3/23 Proposal: 1/9/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SMALL BUSINESS DEVELOPMENT (5)		
47.	Phase I Open Call for Innovative Defense-Related Dual- Purpose Technologies/Solutions with a Clear DAF Stakeholder Need (DoD/Air Force) AFX237-PCSO1 AFX23E-PTCSO1	Primary objectives of this topic include exploring innovative technologies applicable to both defense and non-defense markets, scaling capability, and growing the industrial base for defense. Critical technology areas include AI and Autonomy, Biotechnology, Human-Machine Interfaces, and Advanced Materials. https://media.defense.gov/2023/Aug/28/2003289392/-1/o/AF_SBIR_X23.7_CSO.PDF https://media.defense.gov/2023/Aug/28/2003289394/-1/o/AF_STTR_X23.E_CSO.PDF	Up to \$75,000, for 3 months (SBIR) Up to \$110,000, for 3 months (STTR)	Proposal: 9/28/23
48.	Chemical and Biological Defense SBIR 23.3 Phase I (DoD/DTRA) CBD233	The CBD SBIR Program targets those technology efforts that maximize a strong defensive posture in a biological or chemical environment using passive and active means as deterrents. Current topics include: Real Time Physiological Status Monitor for MicroClimate Control; Breathable, Non-Fluorinated Chemical Barrier Materials; and Development of an early-warning biosensor based on the detection of helical structures in biomolecules. https://media.defense.gov/2023/Aug/22/2003285646/-1/-1/o/CBD_SBIR_233.PDF	Up to \$197,283, for up to 6 months (Phase 1)	Proposal: 10/18/23
49.	DHA SBIR 23.3 Phase I & Direct to Phase II and DHA STTR 23.C (DoD/DHA) DHA233 DHA23C	The Defense Health Agency (DHA) SBIR/STTR Program seeks small businesses with strong research and development capabilities to pursue and commercialize medical technologies. Topics include: Rapid Diagnostic for Invasive Fungal Infection; Novel Fieldable Device for Detection of Sleep Microarousals; Multi-faceted mAb Development Program for Multi-Drug Resistant Wound Infections; Exosome Loaded Antibiotics for Bacterial Wound Infections. https://media.defense.gov/2023/Aug/22/2003285642/-1/-1/o/DHA_SBIR_233_PI_DP2.PDF https://media.defense.gov/2023/Aug/22/2003285638/-1/-1/o/DHA_STTR_23C.PDF	Up to \$250,000, for up to 6 months (Phase I) Up to \$1.3 million, for up to 2 years (Phase II)	Proposal: 10/18/23
50.	A Solicitation of the NIH and The CDC for SBIR Contract Proposals (NIH/CDC) PHS-2024-1	NIH and CDC are soliciting proposals from SBCs that possess the R&D expertise to conduct innovative research that will contribute toward NIH or CDC mission needs and SBIR program objectives. Topics include diagnostics, therapeutics, vaccines, and health IT. View the full list of topics here. https://sam.gov/opp/aa72581c848947f0b61c15062e604862/view	Dependent upon proposal and contract	Proposal: 11/14/23
		SUBSTANCE USE DISORDER (31)		
51.	NOSI: Epidemiology and Prevention in Alcohol Research (NIH/NIAAA/NCI) NOT-AA-23-018	This NOSI solicits applications to advance basic, applied, translational, and methodological research on the epidemiology and prevention of hazardous alcohol consumption and related behaviors, alcohol use disorder, alcohol-related mortality and morbidity, and other alcohol-related problems and consequences. https://grants.nih.gov/grants/guide/notice-files/NOT-AA-23-018.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/6/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SUBSTANCE USE DISORDER		
52.	NOSI: Xylazine: Understanding Its Use and the Consequences (NIH/NIDA) NOT-DA-24-012	The purpose of this NOSI is to encourage research on the prevalence and consequences of xylazine co-use with opioids or opioid/stimulant combinations. This NOSI also encourages research into how xylazine impacts treatment of opioid use disorders and overdose. https://grants.nih.gov/grants/guide/notice-files/NOT-DA-24-012.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/8/25
53.	Alcohol Treatment, Pharmacotherapy, and Recovery Research (R34/R01 Clinical Trial Required) and Alcohol Health Services Research (R01/R34 Clinical Trial Optional) (NIH/NIAAA) PAR-23-249 (R34) PAR-23-250 (R01) PAR-23-251 (R01) PAR-23-252 (R34)	The Clinical Trial Required NOFOs will focus broadly on topics relevant for treatment of and recovery from AUD, including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies. The Clinical Trial Optional NOFOs will broadly focus on closing the treatment gap for individuals with AUD. https://grants.nih.gov/grants/guide/pa-files/PAR-23-249.html (R34) https://grants.nih.gov/grants/guide/pa-files/PAR-23-250.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-23-251.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-23-252.html (R34)	Up to \$500,000, for up to 5 years (R01) Up to \$450,000, for up to 3 years (R34)	Letter of intent: 1/5/24 Proposal: 2/5/24 (R01) Letter of intent: 1/16/24 Proposal: 2/16/24 (R34)
54.	Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional) (NIH/NIDA) PAR-23-253	This NOFO aims to accelerate the development of devices to treat SUDs. The continuing advances in technologies offer unprecedented opportunities to develop neuromodulatory or neurophysiological devices that are safe and effective SUD treatments. The objective is to move devices to their next step in the FDA approval process, with the ultimate goal of generating new, FDA approved device-based treatments for SUDs. https://grants.nih.gov/grants/guide/pa-files/PAR-23-253.html	Up to \$500,000 per year, for up to 2 years (UG3) Dependent upon proposal, for up to 3 years (UH3)	Letter of intent: 11/18/23 Proposal: 12/18/23



Recurring Opportunities

September 6, 2023

<https://www.g2gconsulting.com/gbg-reporting-service/>

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (1)		
55.	Open-Office Broad Agency Announcement (BAA) 75N99223S0001	Awardees will develop groundbreaking new ways to tackle health-related challenges through high-potential, high-impact biomedical and health research. ARPA-H has identified four initial focus areas that are a priority for investment: (1) Health Science Futures; (2) Scalable Solutions; (3) Proactive Health; (4) Resilient Systems. https://sam.gov/opp/cafi09b75a0449418ead3630cef1915e/view	Dependent upon proposal and award mechanism	Abstract: 3/14/24
		AIR FORCE (3)		
56.	Airman Readiness Medical Research (ARMR) Hybrid BAA FA8650-20-S-6008	The Warfighter Medical Optimization Division intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance. https://www.grants.gov/web/grants/view-opportunity.html?oppld=327332	Up to \$49 million, per award	White papers accepted on rolling basis until 4/30/26
57.	Research Interests of the Air Force Office of Scientific Research FA9550-23-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. These areas are organized and managed in two scientific Departments: Engineering and Information Science (RTA), Physical and Biological Sciences (RTB), and our international offices (EAORD, SOARD, and AOARD). https://www.grants.gov/web/grants/view-opportunity.html?oppld=345653	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AIR FORCE		
58.	Research Interests of the United States Air Force Academy USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. https://www.grants.gov/web/grants/view-opportunity.html?oppld=330175	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis
		ARMY (8)		
59.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. https://sam.gov/opp/66870bda25274773b3e5fa7cfd3coe11/view	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
60.	USAMRDC Broad Agency Announcement for Extramural Medical Research HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; Military Operational Medicine; Medical Biological Defense; and Medical Chemical Defense. https://www.grants.gov/web/grants/view-opportunity.html?oppld=343725	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation
61.	USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development HT9425-23-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries; prolonged field care (PFC); human performance optimization; canine medicine/performance; brain health; immune response; automation of systematic reviews and metanalysis; and novel post-traumatic stress, depression, and anxiety treatment. Special Operations Forces (SOF) medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/web/grants/view-opportunity.html?oppld=349586	Dependent upon proposal	Proposals accepted through 7/31/28 Submission of a pre-proposal is required



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
62.	Army Research Office Broad Agency Announcement for Fundamental Research W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition; the full list of research topics is available here: https://www.arl.army.mil/opportunities/arl-baa/ https://sam.gov/opp/e68f40ea3b224b86ab14b9d5a8af7f9c/view	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27
63.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://sam.gov/opp/e8d78dcbe9e846f2af5fd1bfd04dc27c/view	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required
64.	Army Applications Lab BAA for Disruptive Applications W911NF-19-S-0004	AAL is interested in any and all technologies which can be shown to enable the Army of 2028 to be ready to deploy, fight, and win decisively against any adversary, anytime, and anywhere, in a joint, multi- domain, high-intensity conflict, while simultaneously deterring others and maintaining its ability to conduct irregular warfare. https://www.grants.gov/web/grants/view-opportunity.html?oppId=315517	Dependent upon proposal	Proposals accepted through 5/1/24 Pre-proposal is required
65.	Army Research Office Broad Agency Announcement Staff Research Program W911NF20S0003	The purpose of the program is to enable ARO scientific staff to maintain and expand professional competence in support of fulfilling the ARO mission through the conduct of hands-on, basic research. Research efforts will involve scientific study directed toward advancing the state-of-the-art or increasing knowledge and scientific understanding in engineering, physical, life and information sciences. https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf	Dependent upon proposal	Proposals accepted on a rolling basis until 2/19/25
66.	Army Combat Capabilities Development Command Broad Agency Announcement W911QY20R0022	Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest. https://www.grants.gov/web/grants/view-opportunity.html?oppId=327285	Dependent upon proposal	Proposals accepted on a rolling basis until 2/28/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BARDA (2)		
67.	BARDA Broad Agency Announcement BARDABAA	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antibacterials; Radiological, Nuclear & Chemical Threat MCMs; Burn Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; Flexible and Strategic Therapeutics (FASTx); Next-generation COVID-19 Vaccines; ImmuneChip+. https://sam.gov/opp/ob30fe1ef71046d090e0beef36b5234c/view	Dependent upon proposal	White papers: 9/25/23; some AOIs due earlier
68.	BARDA DRIVe EZ-BAA DRIVeEZBAA22100SOL00003	BARDA is currently accepting submissions through the EZ-BAA for several AOIs: AOI #16: Lab at Home; AOI #17: Digital MCMs; AOI #19: Healing Lungs; AOI #20: DRIVe Forward; AOI #21: Vaccines on Demand; AOI #22: ReBooT; AOI #24: REPAIR; AOI #25: FASTx. https://sam.gov/opp/caf2abe4309b4460b4979d01bocabbf2/view	Up to \$750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI
		DARPA (2)		
69.	Biological Technologies BAA HR001123S0045	Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. BTO is interested in submissions related to the following topic areas: Human Performance; Materials, Sensors, Processing; Ecosystem and Environmental; Biosecurity and Biosafety; and Biomedical and Biodefense. https://sam.gov/opp/597bf60984314db1b3ecf393677c75/view	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 6/20/24
70.	Defense Sciences Office, Office-wide HR001122S0041	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Novel Materials & Structures; Sensing and Measurement; Computation and Processing; Enabling Operations; Collective Intelligence; and Global Change. https://sam.gov/opp/d99f59e0d48245e688b92af595380c79/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 9/11/23
		DEFENSE THREAT REDUCTION AGENCY (2)		
71.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) HDTRA1-14-24-FRCWMD-BAA	DTRA seeks to identify, adopt, and adapt emerging, existing and revolutionary sciences that may demonstrate high payoff potential to Counter-WMD (C-WMD) threats. Current thrust areas include global biosurveillance, biosafety, and biosecurity, and chemical and biological defense. https://sam.gov/opp/da2d0850923340169b5263998efe73f6/view	Up to \$1 million per year, for up to 5 years	White papers accepted through 9/2024



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEFENSE THREAT REDUCTION AGENCY		
72.	Research and Development Innovations Broad Agency Announcement HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the 2022 DTRA Strategic Plan for RDT&E (plan available at https://www.dtra.mil/): • Understand current and emerging WMD situations, threats, and capabilities • Enable effective and integrated WMD deterrence • Control, disable, and defeat current and emerging WMD threats • Protect the force and mitigate crises from WMD • Enable cross-cutting capabilities https://sam.gov/opp/e23f86536f7840eaa868f3526a86a6ae/view	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27
		DEPARTMENT OF ENERGY (1)		
73.	FY2023 Continuation of Solicitation for the Office of Science Financial Assistance Program DE-FOA-0002844	By integrating genome science with advanced computational and experimental approaches, the Division seeks to gain a predictive understanding of living systems, from microbes and microbial communities to plants and ecosystems. This foundational knowledge enables design and reengineering of microbes and plants underpinning a broad clean energy and bioeconomy portfolio. https://www.grants.gov/web/grants/view-opportunity.html?oppId=343866	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/23
		NATIONAL SCIENCE FOUNDATION (1)		
74.	Small Business Innovation Research Program Phase I (SBIR/STTR Phase I) NSF 23-515	The NSF SBIR and STTR programs focus on transforming scientific discovery into products and services with commercial potential and/or societal benefit. Unlike fundamental or basic research activities that focus on scientific and engineering discovery itself, the NSF SBIR program supports the creation of opportunities to move fundamental science and engineering out of the lab and into the market or other use at scale, or startups and small businesses representing "deep technology ventures." The programs fund research and development, and are designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development. The required Project Pitch allows startups and small businesses to get quick feedback at the start of their application for Phase I funding. Click here for project pitch details and for the full list of topics click here . https://www.nsf.gov/pubs/2023/nsf23515/nsf23515.htm	Up to \$275,000 for up to 1 year	Project pitches accepted on a rolling basis. Submission window for invited proposals: 7/6/23 to 11/1/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NAVY (3)		
75.	FY23 Broad Agency Announcement for Innovative Environmental Technologies and Methodologies N3943023S2501	This announcement seeks out technologies and methodologies to reduce environmental impacts from current and past Navy operations, and applies to Navy installations worldwide. NEXWC is interested in environmental technologies and methodologies that are either new, innovative, advance the state-of-the art, or increase knowledge or understanding of a technology or methodology. https://sam.gov/opp/14178e9157ad40b387ddb443071b0969/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 4/11/24
76.	Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology N00014-23-S-B001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://www.nre.navy.mil/work-with-us/funding-opportunities/fy23-long-range-broad-agency-announcement-baa-navy-and-marine	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/23
77.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research N00173-23-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. https://sam.gov/opp/58eeca6ef84a4d25b41boedaca42447a/view	Dependent upon proposal and award mechanism	White papers accepted through 9/30/23





Terms

AD/ADDR: Alzheimer's Disease / Alzheimer's Disease Related Dementias

Aol: Area of Interest

BAA: Broad Agency Announcement

BBB: Blood-Brain Barrier

CNS: Central Nervous System

FOA: Funding Opportunity Announcement

IC: NIH Institutes and Centers

NOFO: Notice of Funding Opportunity

NOSI: Notice of Special Interest

PI: Principal Investigator

PTSD: Post-Traumatic Stress Disorder

RFI: Request for Information

RFP: Request for Proposal

SBIR: Small Business Innovation Research

SDOH: Social Determinants of Health

STTR: Small Business Technology Transfer

SUD: Substance Use Disorder

TRL: Technology Readiness Level

VCID: Vascular Contributions to Cognitive Impairment and Dementia

Agencies

ARPA-H: Advanced Research Projects Agency for Health

ASPR: Administration for Strategic Preparedness and Response

BARDA: Biomedical Advanced Research and Development Authority

CDC: Centers for Disease Control and Prevention

CDMRP: Congressionally Directed Medical Research Programs

DARPA: Defense Advanced Research Projects Agency

DHA: Defense Health Agency

DoD: Department of Defense

FDA: U.S. Food and Drug Administration

MTEC: Medical Technology Enterprise Consortium

NIH: National Institutes of Health

[Back to Table of Contents](#)

GBG Acronyms

Updated Monthly

September 6, 2023

<https://www.g2gconsulting.com/gbg-reporting-service/>

NSF: National Science Foundation

PCORI: Patient-Centered Outcomes Research Institute

USAMRDC: U.S. Army Medical Research and Development Command

USAMRIID: U.S. Army Medical Research Institute of Infectious Diseases

USSOCOM: United States Special Operations Command

NIH Institutes and Centers

CC: NIH Clinical Center

CIT: NIH Center for Information Technology

CSR: NIH Center for Scientific Review

FIC: Fogarty International Center

NCATS: National Center for Advancing Translational Sciences

NCCIH: National Center for Complementary and Integrative Health

NCI: National Cancer Institute

NEI: National Eye Institute

NHGRI: National Human Genome Research Institute

NHLBI: National Heart, Lung, and Blood Institute

NIA: National Institute on Aging

NIAAA: National Institute on Alcohol Abuse and Alcoholism

NIAID: National Institute of Allergy and Infectious Diseases

NIAMS: National Institute of Arthritis & Musculoskeletal & Skin Diseases

NIBIB: National Institute of Biomedical Imaging and Bioengineering

NICHD: Eunice Kennedy Shriver National Institute of Child Health and Human Development

NIDA: National Institute on Drug Abuse

NIDCD: National Institute on Deafness and Other Communication Disorders

NIDCR: National Institute of Dental and Craniofacial Research

NIDDK: National Institute of Diabetes and Digestive and Kidney Diseases

NIEHS: National Institute of Environmental Health Sciences

NIGMS: National Institute of General Medical Sciences

NIMH: National Institute of Mental Health

NIMHD: National Institute on Minority Health and Health Disparities

NINDS: National Institute of Neurological Disorders and Stroke

NINR: National Institute of Nursing Research

NLM: National Library of Medicine

